<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2007

                                       OR

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     FOR THE TRANSITION PERIOD FROM __________ TO __________

                        COMMISSION FILE NUMBER: 000-25132

                              MYMETICS CORPORATION
             (Exact name of Registrant as specified in its charter)

<TABLE>
<S>                                                          <C>
            DELAWARE                                              25-1741849
(State or other jurisdiction of                                (I.R.S. Employer
 incorporation or organization)                              Identification No.)
</TABLE>

                            European Executive Office
                            14, rue de la Colombiere
                             1260 Nyon (Switzerland)
                    (Address of principal executive offices)

                               011 41 22 363 13 10
              (Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [X]

Indicate by check mark whether the Registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Indicate the number of shares outstanding of each of the Registrant's classes of
common stock, as of the latest practicable date:

<TABLE>
<CAPTION>
Class                     Outstanding at July 17, 2007
-----                     ----------------------------
<S>                       <C>
Common Stock, U.S.$0.01
   par value                      173,096,964
</TABLE>
<PAGE>

                          PART I. FINANCIAL INFORMATION

                          ITEM 1. FINANCIAL STATEMENTS

                              MYMETICS CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
                           CONSOLIDATED BALANCE SHEETS
                                   (UNAUDITED)
                             (IN THOUSANDS OF EUROS)

<TABLE>
<CAPTION>
                                                              June 30,   December 31,
                                                                2007         2006
                                                              --------   ------------
<S>                                                           <C>        <C>
ASSETS
Current Assets
   Cash                                                       E     77     E     29
   Receivables                                                      --           15
   Prepaid expenses                                                229           16
                                                              --------     --------
      Total current assets                                         306           60
Patents and licenses                                               466          300
                                                              --------     --------
                                                              E    772     E    360
                                                              ========     ========
LIABILITIES AND SHAREHOLDERS'
EQUITY (DEFICIT)
Current Liabilities
   Accounts payable                                           E  1,605     E  1,933
   Taxes and social costs payable                                   --            5
   Current portion of notes payable                                 --        4,021
   Other                                                             7          288
                                                              --------     --------
      Total current liabilities                                  1,612        6,247
Payable to Shareholders                                             --          242
Notes Payable to shareholders                                      151          351
                                                              --------     --------
      Total liabilities                                          1,763        6,840
Shareholders' Equity (Deficit)
   Common stock, U.S. $.01 par value; 495,000,000 shares
      authorized; issued and outstanding
      170,196,964 at June 30, 2007 and
      110,690,464 at December 31, 2006                           1,568        1,061
   Common stock issuable; 2,900,000 shares at June 30, 2007
      And 330,000 shares at December 31, 2006                       22            3
   Preferred stock, U.S. $.01 par value; 5,000,000 shares
      authorized; none issued or outstanding                        --           --
   Additional paid-in capital                                   15,329        7,381
   Deficit accumulated during the development stage            (18,656)     (15,672)
   Accumulated other comprehensive income                          746          747
                                                              --------     --------
                                                                  (991)      (6,480)
                                                              --------     --------
                                                              E    772     E    360
                                                              ========     ========
</TABLE>

The accompanying notes are an integral part of these financial statements.

<PAGE>

                              MYMETICS CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
          CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
                                   (UNAUDITED)
              (IN THOUSANDS OF EUROS, EXCEPT FOR PER SHARE AMOUNTS)

<TABLE>
<CAPTION>
                                    FOR THE SIX     FOR THE SIX    TOTAL ACCUMULATED
                                    MONTHS ENDED    MONTHS ENDED       DURING THE
                                   JUNE 30, 2007   JUNE 30, 2006   DEVELOPMENT STAGE
                                   -------------   -------------   -----------------
<S>                                <C>             <C>             <C>
Revenue
   Sales                              E    --         E   --           E    224
   Interest                                --             --                 34
                                      -------         ------           --------
                                           --             --                258
                                      -------         ------           --------
Expenses
   Research and development               218            319              5,847
   General and administrative           2,651            261              9,774
   Bank fee                                --             --                935
   Interest                               106            125              1,337
   Goodwill impairment                     --             --                209
   Amortization                             9             50                522
   Directors' fees                         --             --                274
   Other                                   --             --                 10
                                      -------         ------           --------
                                        2,984            755             18,908
                                      -------         ------           --------
Loss before income tax provision       (2,984)          (755)           (18,650)
Income tax provision                       --             --                 (6)
                                      -------         ------           --------
Net loss                               (2,984)          (755)           (18,656)
Other comprehensive income
   Foreign currency translation
      adjustment                           (1)            20                746
                                      -------         ------           --------
Comprehensive loss                    E(2,985)        E (735)          E(17,910)
                                      =======         ======           ========
Basic and diluted loss per share      E (0.02)        E(0.01)
                                      =======         ======
</TABLE>

The accompanying notes are an integral part of these financial statements.
<PAGE>

                              MYMETICS CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
          CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
                                   (UNAUDITED)
              (IN THOUSANDS OF EUROS, EXCEPT FOR PER SHARE AMOUNTS)

<TABLE>
<CAPTION>
                                   FOR THE THREE   FOR THE THREE
                                    MONTHS ENDED    MONTHS ENDED
                                   JUNE 30, 2007   JUNE 30, 2006
                                   -------------   -------------
<S>                                <C>             <C>
Revenue
   Sales                              E    --         E   --
   Interest                                --             --
                                      -------         ------
                                           --             --
                                      -------         ------
Expenses
   Research and development                70            223
   General and administrative           2,480             62
   Bank fee                                --             --
   Interest                                29             63
   Goodwill impairment                     --             --
   Amortization                             5             25
   Directors' fees                         --             --
   Other                                   --             --
                                      -------         ------
                                        2,584            373
                                      -------         ------
Loss before income tax provision       (2,584)          (373)
Income tax provision                       --             --
                                      -------         ------
Net loss                               (2,584)          (373)
Other comprehensive income
   Foreign currency translation
      adjustment                           (5)            10
                                      -------         ------
Comprehensive loss                    E(2,589)        E (363)
                                      =======         ======
Basic and diluted loss per share      E (0.02)        E(0.00)
                                      =======         ======
</TABLE>

The accompanying notes are an integral part of these financial statements.

<PAGE>

                              MYMETICS CORPORATION
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
                             (IN THOUSANDS OF EUROS)

<TABLE>
<CAPTION>
                                                FOR THE SIX     FOR THE SIX    TOTAL ACCUMULATED
                                                MONTHS ENDED    MONTHS ENDED       DURING THE
                                               JUNE 30, 2007   JUNE 30, 2006   DEVELOPMENT STAGE
                                               -------------   -------------   -----------------
<S>                                            <C>             <C>             <C>
Cash flow from operating activities
Net Loss                                          E(2,984)         E(755)           E(18,656)
Adjustments to reconcile net loss to
   net cash used in operating activities
      Amortization                                      9             50                 522
      Goodwill impairment                              --             --                 209
      Fees paid in warrants                            --             --                 223
      Services and fee paid in common stock         2,421             --               4,415
      Amortization of debt discount                    --             --                 210
Changes in current assets and
   liabilities, net of effects
   from reverse purchase in a prior period
      Decrease(increase) in receivables                15            (35)                 38
      Increase(decrease) in accounts payable         (328)           236               1,587
      Increase(decrease) in taxes and                  (5)            --                  --
      social costs payable
         Increase(decrease)in Other                  (494)           (11)               (174)
                                                  -------          -----            --------
Net cash used in operating activities              (1,366)          (515)            (11,626)
                                                  -------          -----            --------
Cash flows from investing activities
   Patents and other                                 (175)          (323)               (868)
   Cash acquired in reverse purchase                   --             --                  13
                                                  -------          -----            --------
Net cash used in investing activities                (175)          (323)               (855)
                                                  -------          -----            --------
Cash flows from financing activities
   Proceeds from issuance of common stock           2,350            665               7,365
   Borrowing from shareholders                        730             --                 972
   Increase in note payable and other
      short-term advances                              --            237               5,095
   Decrease in note payable and other
      short-term advances                          (1,490)            --              (1,490)
   Loan fees                                           --             --                (130)
                                                  -------          -----            --------
Net cash provided by financing activities           1,590            902              11,812
                                                  -------          -----            --------
Effect on foreign exchange rate on cash                (1)            20                 746
                                                  -------          -----            --------
Net change in cash                                     48             84                  77
Cash, beginning of period                              29             70                  --
                                                  -------          -----            --------
Cash, end of period                               E    77          E 154            E     77
                                                  =======          =====            ========
</TABLE>

The accompanying notes are an integral part of these financial statements.
<PAGE>

                              MYMETICS CORPORATION
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                  JUNE 30, 2007
                                   (UNAUDITED)

Note 1. The Company and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim period consolidated financial statements of Mymetics
Corporation (the "Company") set forth herein have been prepared by the Company
pursuant to the rules and regulations of the U.S. Securities and Exchange
Commission (the "SEC"). Certain information and footnote disclosure normally
included in financial statements prepared in accordance with accounting
principles generally accepted in the United States have been condensed or
omitted pursuant to such SEC rules and regulations. The interim period
consolidated financial statements should be read together with the audited
financial statements and the accompanying notes included in the Company's latest
annual report on Form 10-K for the fiscal year ended December 31, 2006.

The accompanying financial statements of the Company are unaudited. However, in
the opinion of the Company, the unaudited consolidated financial statements
contained herein contain all adjustments necessary to present a fair statement
of the results of the interim periods presented. All adjustments made during the
six-month period ended June 30, 2007 were of a normal and recurring nature.

The amounts presented for the six-month period ended June 30, 2007, are not
necessarily indicative of the results of operations for a full year.

The amounts in the notes are rounded to the nearest thousand of Euros except for
per share amounts.

The Company was created for the purpose of engaging in research and development
of human health products. Its main research efforts have been concentrated in
the prevention and treatment of the HIV-AIDS virus. The Company has established
a network which enables it to work with education centers, research centers,
pharmaceutical laboratories and biotechnology companies.

These financial statements have been prepared treating the Company as a
development stage company. As of June 30, 2007, the Company had not performed
any human clinical testing and revenues obtained from the sale or licensing of
the Company's technology are not expected before 2009 at the earliest. As such,
the Company has not generated significant revenues. Revenues reported by the
Company consist of incidental serum by-products of the Company's research and
development activities and interest income. For the purpose of these financial
statements, the development stage started May 2, 1990.

These financial statements have been prepared assuming the Company will continue
as a going concern. The Company has experienced significant losses since
inception resulting in a deficit in shareholders' equity (deficit) of E18,656 at
June 30, 2007. Deficits in operating cash flows since inception have been
financed through debt and equity funding sources. In order to remain a going
concern and continue the Company's research and development activities,
management intends to seek additional funding. Further, the Company's current
liabilities exceed its current assets by E1,306 as of June 30, 2007, and there
is no assurance that cash will become available to pay current liabilities in
the near term. Management is seeking additional financing but there can be no
assurance that management will be successful in any of those efforts.

Principles of Consolidation

<PAGE>

The consolidated financial statements include the accounts of the Company and
its subsidiaries. Significant intercompany accounts and transactions have been
eliminated.

Foreign Currency Translation

The Company translates non-Euro assets and liabilities of its subsidiaries at
the rate of exchange at the balance sheet date. Revenues and expenses are
translated at the average rate of exchange throughout the year. Unrealized gains
or losses from these translations are reported as a separate component of
comprehensive income. Transaction gains or losses are included in general and
administrative expenses in the consolidated statements of operations. The
translation adjustments do not recognize the effect of income tax because the
Company expects to reinvest the amounts indefinitely in operations. The
Company's reporting currency is the Euro because substantially all of the
Company's activities are conducted in Europe.

Receivables

Receivables are stated at their outstanding principal balances. Management
reviews the collectibility of receivables on a periodic basis and determines the
appropriate amount of any allowance. Based on this review procedure, management
has determined that the allowances at June 30, 2007 and December 31, 2006 are
sufficient. The Company charges off receivables to the allowance when management
determines that a receivable is not collectible.

Current liabilities

On June 8, 2007, a shareholder agreed to convert three short term notes
totalling E930,000 into restricted Company's shares at an average price of
$0.137 per share, market price being $0.105 on that day.

Research and Development

Research and development costs are expensed as incurred.

Taxes on Income

The Company accounts for income taxes under an asset and liability approach that
requires the recognition of deferred tax assets and liabilities for expected
future tax consequences of events that have been recognized in the Company's
financial statements or tax returns. In estimating future tax consequences, the
Company generally considers all expected future events other than enactments of
changes in the tax laws or rates.

Earnings per Share

Basic earnings per share is computed by dividing income available to common
shareholders by the weighted average number of common shares outstanding in the
period. The weighted average number of shares was 130,516,481 and 93,540,354 for
the six months ended June 30, 2007 and 2006, respectively. Diluted earnings per
share takes into consideration common shares outstanding (computed under basic
earnings per share) and potentially dilutive securities. Warrants and options
were not included in the computation of diluted earnings per share because their
effect would be anti-dilutive due to net losses incurred.

Stock-Based Compensation

<PAGE>

The Company accounts for stock based compensation using the fair value
recognition provisions of FAS No. 123(R), Share-Based Payment, ("FAS 123R").

If the fair value method under FAS 123R had been applied since inception,
additional compensation costs of E320 would have been recorded. The expense for
stock options and warrants to purchase stock granted is measured using a fair
value valuation model at the date of grant multiplied by the number of options
granted.

The fair value of each option granted was estimated for pro forma purposes on
the grant date using the Black-Scholes model (use of this model for pro forma
purposes is not intended to indicate the value of the Company as a whole). There
were no options issued in 2007 and 2006.

The issuance of common shares for services is recorded at the quoted price of
the shares on the date the services are rendered.

Issuance of shares

From January 1, 2007, through June 30, 2007, the Company has issued common stock
as follows:

-    12,500,000 in exchange for long-term debt of E2,598,

-    2,957,500 shares in exchange for services valued at E210,

-    16,000,000 shares for management bonuses valued at E2,152,

-    9,469,000 shares in exchange for short-term debt and interest payable to a
     shareholder of E961,

-    18,900,000 shares in exchange for cash of E2,282,

-    2,250,000 shares in exchange for a reduction in accounts payable of E29.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
     OF OPERATIONS

GENERAL

The following discussion and analysis of the results of operations and financial
condition of Mymetics Corporation for the periods ended June 30, 2007 and 2006
should be read in conjunction with the Company's audited consolidated financial
statements and related notes and the description of the Company's business and
properties included elsewhere herein.

This report contains forward-looking statements that involve risks and
uncertainties. The statements contained in this report are not purely
historical, but are forward-looking statements within the meaning of Section 21E
of the Securities Exchange Act of 1934, as amended, and Section 27A of the
Securities Act of 1933, as amended. These forward looking statements concern
matters that involve risks and uncertainties that could cause actual results to
differ materially from those projected in the forward-looking statements. Words
such as "may," "will," "should," "could," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential," "continue", "probably" or similar
words are intended to identify forward looking statements, although not all
forward looking statements contain these words.

Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of
activity performance or achievements. Moreover, neither we nor any other person
assumes responsibility for the accuracy and completeness of the forward-looking
statements. We are under no duty to update any of the forward-looking statements
after the date hereof to conform such statements to actual results or to changes
in our expectations.

Readers are urged to carefully review and consider the various disclosures made
by us which attempt to advise interested parties of the factors which affect our
business, including without limitation disclosures made under the captions
"Management Discussion and Analysis of Financial Condition and Results of
Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to

<PAGE>

Consolidated Financial Statements" included in our annual report on Form 10-K
for the year ended December 31, 2006 and, to the extent included therein, our
quarterly reports on Form 10-Q filed during fiscal year 2006.

SIX MONTHS ENDED JUNE 30, 2007 AND 2006

Revenue was nil for the six months ended June 30, 2007 and June 30, 2006.

Costs and expenses increased to E2,984,000 for the six months ended June 30,
2007 from E755,000 (295.2%) for the six months ended June 30, 2006. Research and
development expenses decreased to E218,000 in the current period from E319,000
(-31.7%) in the comparative period of 2006 as we are now preparing phase I of
our human clinical tests. General and administrative expenses increased to
E2,651,000 in the six months ended June 30, 2007 from E261,000 in the
comparative period of 2006 (915.7%) mostly due to the fact that the comparative
period of 2007 included the cost of the settlement with MFC Merchant Bank S.A.
as well as the cost of the shares issued as bonus to our management.

The Company reported a net loss of E2,984,000, or E0.02 per share, for the six
months ended June 30, 2007, compared to a net loss of E755,000, or E0.01 per
share, for the six months ended June 30, 2006.

LIQUIDITY AND CAPITAL RESOURCES

The Company had cash of E77,000 at June 30, 2007 compared to E29,000 at December
31, 2006.

We have not generated any material revenues since we commenced our current line
of business in 2001, and we do not anticipate generating any material revenues
on a sustained basis unless and until a licensing agreement or other commercial
arrangement is entered into with respect to our technology.

Increases in borrowing from our shareholders provided cash of E730,000 in the
current period compared to nil during the six months ended June 30, 2006.
Settlement of a non-revolving term facility in the principal amount of up to
E3.7 million, under which Mymetics had borrowed an aggregate of E4,021,000, used
cash of E1,490,000. The balance of E2,531,000 was settled in exchange for 12.5
million shares of common stock.

As of June 30, 2007, we had an accumulated deficit of approximately E18.7
million, and we incurred losses of E2,984,000 in the six-month period ending on
that date. These losses are principally associated with the research and
development of our HIV vaccine technologies as well as the settlement of our
dispute with MFC Merchant Bank SA and the issuance of bonus shares to our
officers. We expect to continue to incur expenses in the future for research,
development and activities related to the future licensing of our technologies.

Accounts payable of E1,605,000 at June 30, 2007, include E198,000 due to our
officers as unpaid salaries, fees and out-of-pocket expenses.

Net cash used in operating activities was E1,366,000 for the period ended June
30, 2007, compared to E515,000 for the period ended June 30, 2006, mostly due to
the cost of our settlement with MFC Merchant Bank S.A., the cost of shares
issued as bonus to our management and the prepayments we had to do to strategic
partners involved in the preparation of our phase I human clinical tests due to
begin in 2008.

Investing activities used cash of E175,000 during the six months ended June 30,
2007, entirely for the acquisition of strategic license rights, as compared to
E323,000 used during the six months ended June 30, 2006, entirely for the
application of new patents.

<PAGE>

Financing activities provided cash of E1,590,000 for the period ended June 30,
2007 compared to E902,000 in the same period last year.

Proceeds from issuance of common stock provided E2,350,000 during the period
ended June 30, 2007 compared to E665,000 in the same period in 2006. The
increase is essentially due to the settlement of the litigation with MFC
Merchant Bank S.A., under which E990,000 was provided by a shareholder to
finance the settlement. Additionally, included as part of borrowings from
shareholders, is E500,000 which was received as a short term loan and was used
as part of the settlement. The short term loan was converted into common stock
in June 2007.

Salaries and related payroll costs represent fees for all of our directors other
than our employee directors, gross salaries for two of our executive officers,
and payments under consulting contracts with two of our officers. We do not pay
our non-employee directors, and we credit our salaried executive officers a
combined amount of E54,000 per month under Executive Employment Agreements with
our CEO, CFO and CSO approved by our Board of Directors on July 1, 2006.

Since January 15, 2004, payments of E4,000 per month for Professor Marc Girard's
services as our Head of Vaccines Development were due pursuant to a consulting
agreement dated June 10, 2004, as disclosed in our filing on Form 10-Q for the
period ended June 30, 2004 to the Securities and Exchange Commission. We have
not been able to make the payments due under the agreement on a regular basis,
and we owed Professor Girard approximately E59,000 at June 30, 2007.

Monthly fixed and recurring expenses for "Property leases" of E1,200 represents
the monthly lease and maintenance payments to unaffiliated third parties for our
executive offices located at 14, rue de la Colombiere in Nyon (Switzerland) (600
square feet), which can be cancelled on six months notice. We also lease minimal
office facilities for Dr. Fleury at a monthly cost of E1,000, which includes
full access to medical databases over high speed internet connection. This lease
can be cancelled on very short term notice as we are planning to lease in the
next few months facilities to conduct quality checks and to verify scientific
results.

Included in professional fees are estimated recurring legal fees paid to outside
corporate counsel and ongoing litigation expenses, audit and review fees paid to
our independent accountants, and fees paid for investor relations.

Interest expense of E106,000 includes E38,000 interest paid on notes payable to
shareholders and E68,000 interest paid to MFC Merchant Bank S.A. for a note
payable, repaid on March 19, 2007. This note payable in the maximum principal
amount of E3.7 million carried an interest rate of Libor + 4% which was accrued
on a quarterly basis.

As of June 30, 2007, we had three full-time salaried executives, exclusive of
our contracts for the consulting services of Professor Girard, our Head of
Vaccines Development, and one part-time temporary assistant to our CFO. Certain
secretarial work for our CEO is outsourced to a self-employed secretary who
accepts being partially paid in common stock of Mymetics at the current market
price.

We anticipate hiring an assistant to our CFO as well as a part-time laboratory
technician in 2007, and may need to hire additional personnel to meet the needs
and demands of any future workload.

We intend to continue to incur additional expenditures during the next 12 months
for additional research and development of our HIV vaccines. These expenditures
will relate to the continued gp41 testing and are included in the monthly cash
outflow described above. Additional funding requirements during the next 12
months will arise if we commence a phase I clinical trial, which we expect to
occur during 2007. We expect that funding for the cost of any clinical trials
would be available either from debt or equity financings, donors and/or
potential pharmaceutical partners before we commence the human trials.

<PAGE>

In the past we have financed our research and development activities primarily
through debt and equity financings from various parties.

We anticipate our operations will require approximately E8 million until
December 31, 2009, when our phase I human clinical tests are expected to be
completed. We will seek to raise the required capital from equity or debt
financings, donors and/or potential partnerships with major international
pharmaceutical and biotechnology firms. However, there can be no assurance that
we will be able to raise additional capital on terms satisfactory to us, or at
all, to finance our operations. In the event that we are not able to obtain such
additional capital, we would be required to further restrict or even halt our
operations.

RECENT FINANCING ACTIVITIES

To date we have generated no material revenues from our business operations. We
are unable to predict when or if we will be able to generate revenues from
licensing our technology or the amounts expected from such activities. These
revenue streams may be generated by us or in conjunction with collaborative
partners or third party licensing arrangements, and may include provisions for
one-time, lump sum payments in addition to ongoing royalty payments or other
revenue sharing arrangements. However, we presently have no commitments for any
such payments.

Sources of additional capital include funding through future collaborative
arrangements, licensing arrangements, and debt and equity financings. We do not
know whether additional financing will be available on commercially acceptable
terms when needed. If we cannot raise funds on acceptable terms when needed, we
may not be able to successfully commercialize our technologies, take advantage
of future opportunities, or respond to unanticipated requirements. If we are
unable to secure such additional financing when needed, we will have to curtail
or suspend all or a portion of our business activities and we could be required
to cease operations entirely. Further, if we issue equity securities, our
shareholders may experience severe dilution of their ownership percentage.

We are presently engaged in raising the equivalent of E8 million from Swiss and
other non-US investors under Regulation S under the Securities Act of 1933 in
the form of Convertible Notes at staggered conversion prices between $0.30 and
$0.80 (depending on the date committed). This method was preferred to straight
sales of shares at current market price as we and our new investors believe that
the market price presently does not accurately reflect the value of our common
stock but only reflects our past and the difficulty we face in communicating our
results to the public due to the complex scientific issues involved and the
requirements of secrecy under patent laws, which preclude us from communicating
our latest results until the relevant patent applications become public eighteen
months after filing.

In parallel with the effort to raise additional capital from non-US investors as
described above, we have also initiated a fund raising program of $6 million in
the United States under Regulation D under the Securities Act of 1933.

We anticipate using our current funds and those we receive in the future both to
meet our working capital needs and for funding the ongoing research costs
associated with our gp41 testing. Provided we can obtain sufficient financing
resources, we expect to begin phase I clinical trials in 2007. In accordance
with our past strategy, we intend to subcontract such work to "best of class"
research teams unless institutions such as the US National Institutes of Health
(NIH) or the French CEA decide to conduct it at their own expenses, which they
presently do.

We do not anticipate that our existing capital resources will be sufficient to
fund our cash requirements through the next six months. We do not have enough
cash presently on hand, based upon our current levels of expenditures and
anticipated needs during this period, and we will need additional proceeds from

<PAGE>

additional equity investments such as private placements under Regulation D and
Regulation S under the Securities Act of 1933. The extent and timing of our
future capital requirements will depend primarily upon the rate of our progress
in the research and development of our technologies, our ability to enter into a
partnership agreement with a major pharmaceutical company, and the results of
future clinical trials.

To become both eligible for humanitarian grants and attractive to potential
partners, the Company has decided to create a non-profit entity in Monaco to
further R&D specifically aimed at poverty-stricken regions, mostly in Africa and
Asia, generally affected by the Clade C of the HIV virus, and to eventually
distribute specific preventive vaccines in said regions in partnership with
reputable governmental and non-governmental organizations. Under this plan, the
Company will receive mandates from the Monaco entity to perform specific
clinical tests in Africa and other poverty-stricken regions and will commit to
eventually produce under contract preventive vaccines on a "cost-plus" basis.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements.

TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS

<TABLE>
<CAPTION>
                                                    PAYMENTS DUE BY PERIOD
                                                     (THOUSANDS OF EUROS)
                                           ----------------------------------------
                                                    LESS                     MORE
                                                    THAN    1 - 3   3 - 5    THAN
CONTRACTUAL OBLIGATION                     TOTAL   1 YEAR   YEARS   YEARS   5 YEARS
----------------------                     -----   ------   -----   -----   -------
<S>                                        <C>     <C>      <C>     <C>     <C>
Long-term debt (1)                           151      151    E  0     E0       E0
Capital Lease Obligations                  E   0    E   0    E  0     E0       E0
Operating Lease Obligations (2)               10       10    E  0     E0       E0
Purchase Obligations (3)                    1375      975     400     E0       E0
Other Long-Term Liabilities Reflected on
   Mymetics Balance Sheet under GAAP       E   0    E   0    E  0     E0       E0
                                           -----    -----    ----    ---      ---
TOTAL                                       1526     1126     400     E0       E0
                                           =====    =====    ====    ===      ===
</TABLE>

(1)  Short term note due to a shareholder and director

(2)  Office leases in case of cancellation

(3)  Of which two E400 installments for Virosome license fee and E575 for GMP
     Grade peptides and proteins for phase I human clinical trials, of which
     229,000 prepaid

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from changes in interest rates which could affect
our financial condition and results of operations. We have not entered into
derivative contracts for our own account to hedge against such risk.

INTEREST RATE RISK

Fluctuations in interest rates may affect the fair value of financial
instruments. An increase in market interest rates may increase interest payments
and a decrease in market interest rates may decrease interest payments of such
financial instruments. We have no debt obligations which are sensitive to
interest rate fluctuations as our only remaining note payable carries a fixed
rate of 10% p.a.

<PAGE>

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures. As of the end of the registrant's fiscal
year ended December 31, 2006, an evaluation of the effectiveness of the
registrant's "disclosure controls and procedures" (as such term is defined in
Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act")) was carried out by the registrant's principal executive
officer and principal financial officer. Based upon that evaluation, the
registrant's principal executive officer and principal financial officer have
concluded that as of the end of that fiscal year, the registrant's disclosure
controls and procedures are effective to ensure that information required to be
disclosed by the registrant in reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in Securities and Exchange Commission rules and forms.

It should be noted that while the registrant's principal executive officer and
principal financial officer believe that the registrant's disclosure controls
and procedures provide a reasonable level of assurance that they are effective,
they do not expect that the registrant's disclosure controls and procedures or
internal control over financial reporting will prevent all errors and fraud. A
control system, no matter how well conceived or operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are exposed to routine litigation incident to our business. Our policy is to
defend vigorously only the suits with material amounts being sought in damages
and after considering the potential legal costs involved. We do not currently
maintain any liability insurance but are planning to purchase such insurance as
soon as our financial resources will allow it.

Following over a year of litigation initiated by a former director, our French
subsidiary, Mymetics S.A., was ordered by a French court to liquidate and sold
its patents to Lomastar Sarl. All previously disclosed financial items related
to Mymetics S.A. have now been either reversed or written off, such as E242 due
to said former director under the French legal concept of "Return to better
fortune", which is not due anymore by virtue of the liquidation, or the E175
provision set up in anticipation of a possible adverse ruling in the case of
said litigation.

We are in the process of negotiating an agreement with Lomastar Sarl under which
we expect to regain control of the patents for a reasonable royalty payment. Our
management believes that an inability to work out an arrangement for control of
the patents formerly owned by Mymetics S.A. would not have a material adverse
effect on our results of operations in future periods.

ITEM 1A. RISK FACTORS

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the period ended June 30, 2007, we issued 36,819,500 shares for a total
of E4,652,000 and elimination of E930,000 of debt. Of these shares, 16.0 million
were issued to our officers as bonus for hardship endured and results achieved
since 2003, 14.9 million were issued to Anglo Irish bank (Suisse) S.A. (of which
9.5 million to convert notes payable totalling E930,000), 1 million to Franz von
Meyenburg and 0.75 million to SCI Etoile de Mer (Monaco) to finance our
activities.

<PAGE>

During that same second quarter, an aggregate of 1.7 million shares were issued
to four individuals for services rendered and 0.3 million as partial fee for a
key license received.

On June 29, 2007, we issued to Denis Francois 2,250,000 additional shares that
were inadvertently not issued to him. Mr.Francois had already received 2,307,000
shares in connection with an investment that he made in our company in 2005.

All of the foregoing issuances were made in reliance upon the exemption from
registration provided by Section 4(2) under the Securities Act in reliance,
among other things, upon the fact that there was a limited number of recipients,
there was no general solicitation of offers and all of the recipients were
accredited investors.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

<TABLE>
<CAPTION>
EXHIBIT
 NUMBER   DESCRIPTION
-------   -----------
<S>       <C>
31.1      Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2      Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32        Section 1350 Certification of Chief Executive Officer and Chief
          Financial Officer
</TABLE>

<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: July 17, 2007                    MYMETICS CORPORATION


                                        By: /s/ Christian Rochet
                                            ------------------------------------
                                            President and Chief Executive
                                            Officer